Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
49.81
-1.36 (-2.66%)
Apr 9, 2026, 9:42 AM EDT - Market open
Twist Bioscience Revenue
Twist Bioscience had revenue of $103.70M in the quarter ending December 31, 2025, with 16.89% growth. This brings the company's revenue in the last twelve months to $391.56M, up 18.59% year-over-year. In the fiscal year ending September 30, 2025, Twist Bioscience had annual revenue of $376.57M with 20.32% growth.
Revenue (ttm)
$391.56M
Revenue Growth
+18.59%
P/S Ratio
8.01
Revenue / Employee
$399,956
Employees
979
Market Cap
3.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | - | - |
| Jun 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | - | - |
| Jun 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.10B |
| Charles River Laboratories International | 4.02B |
| Revvity | 2.86B |
| Qiagen | 2.09B |
| RadNet | 2.04B |
| Sotera Health Company | 1.16B |
| NeoGenomics | 727.33M |
| Veracyte | 517.15M |
TWST News
- 7 weeks ago - Twist Bioscience to Present at Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement - Business Wire
- 2 months ago - Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes - Business Wire
- 2 months ago - These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results - Benzinga
- 2 months ago - Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Why Is Twist Bioscience Stock Soaring Monday? - Benzinga
- 2 months ago - Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results - Business Wire
- 3 months ago - Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue - Business Wire